Velneperit
Appearance
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H24F3N3O3S |
Molar mass | 407.45 g·mol−1 |
3D model (JSmol) | |
| |
|
Velneperit (S-2367) is a drug developed by Shionogi, which acts as a potent and selective antagonist for the Neuropeptide Y receptor Y5. It has anorectic effects and was developed as a possible treatment for obesity, but was discontinued from further development after disappointing results in Phase II clinical trials. However it was still considered a successful proof of concept of the potential of Y5 receptor antagonists as possible anti-obesity agents in future.[1][2][3]
References
- ^ Yukioka H (November 2010). "[A potent and selective neuropeptide Y Y5-receptor antagonist, S-2367, as an anti-obesity agent]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 136 (5): 270–4. doi:10.1254/fpj.136.270. PMID 21079365.
- ^ Oda S, Manaka K, Kakiya K, Hozumi Y, Fukui Y, Omura S, et al. (April 2015). "Development of an Optimized Synthetic and Purification Process of S-2367 (Velneperit), a Novel Neuropeptide Y (NPY) Y5 Receptor Antagonist". Organic Process Research & Development. 19 (4): 531–6. doi:10.1021/acs.oprd.5b00023.
- ^ George M, Rajaram M, Shanmugam E (January 2014). "New and emerging drug molecules against obesity". Journal of Cardiovascular Pharmacology and Therapeutics. 19 (1): 65–76. doi:10.1177/1074248413501017. PMID 24064009.
Template:Neuropeptide agonists and antagonists